ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
bringing together oncologists and oncology-focused healthcare professionals across the Empire State
Meetings & Education
Financial Advocacy & Patient Assistance
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
ESHOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Pembrolizumab for First-Line Treatment of Metastatic Squamous NSCLC
On October 30, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc.) in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).
Read the full FDA press release here
Tweets by OSSatACCC